SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

December 21, 2009 09:00 ET

UV Flu Technologies Enters Indoor Air Quality Market and Announces Launch of Bio Technology Based Air Purification Product

CENTERVILLE, MA--(Marketwire - December 21, 2009) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") wishes to advise it has recently acquired the assets of AmAirpure, Inc. in order to implement management's plans to move forward as an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality("IAQ") industry sector.

The Company is very pleased today to announce the launch of its flagship product, the UV 400 VIRAGUARD, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to actually trap and destroy harmful microbes. Extensive independent testing by EPA and FDA certified laboratories confirms the proprietary system captures and kills many airborne bacteria and viruses including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Recent statistics show that the U.S. IAQ market generated over $7.7 billion in 2008 with the equipment segment accounting for $3.6 billion. Early year end results for 2009 show continued strength across the entire sector. Continuing attention given to the health effects of toxic mold, the outbreak of infectious diseases such as swine flu, and the increase in chronic respiratory diseases such as asthma have resulted in significant interest and growth in this rapidly growing market.

As a result of the coveted FDA listing as a medical device, UV Flu Technologies is confidently ramping up production towards servicing sales into the early adopter target market sector which includes high risk environments such as hospitals, medical practitioner's offices and institutions. Future sales efforts are anticipated to broaden the scope to include a wide variety of public facilities and consumer interests.

As of December 16, 2009, UV Flu Technologies, Inc. entered into an Asset Purchase Agreement with AmAirpure, Inc., whereby the Company acquires certain of their assets relating to the design, development, manufacture, sale and distribution of technology and products including air purification systems. The agreement includes the transfer of certain shares and contains customary representations and warranties and indemnification provisions.

Further details regarding the Company, its business, financial condition, agreements and management are all filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


UV Flu Technologies, Inc.
John J. Lennon, President & CEO

Contact Information